MedTrace Logo

Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment

NCT02860234 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 68

Last updated 2021-07-23

No results posted yet for this study

Summary

This study is designed to test the efficacy of tailored operative or non-operative management (NOM) for MRI defined low-risk rectal cancer following neoadjuvant intensity modulated radiotherapy with concurrent capecitabine plus consolidation CapeOX. The main purpose of this study is to increase organ-preservation rate for low-risk rectal cancer patients.

Conditions

Interventions

DRUG

Oxaliplatin

DRUG

Capecitabine

RADIATION

intensity modulated radiotherapy

PROCEDURE

DRE-Endoscopy-MRI-CEA

PROCEDURE

Nonoperative Management

PROCEDURE

Local Excision

PROCEDURE

Total Mesorectal Excision

BEHAVIORAL

Quality of Life Questionnaires

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2019-11-30
Completion
2019-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02860234 on ClinicalTrials.gov